Therapy for Pediatric Hodgkin Lymphoma

This study will evaluate the following objectives:

Primary Objectives:

1. To evaluate the efficacy of 4 cycles of VAMP chemotherapy alone in patients with
favorable risk Hodgkin's disease who achieve a complete response after 2 cycles of VAMP
chemotherapy.

2. To evaluate the efficacy of 4 cycles VAMP chemotherapy plus low dose RT in patients with
favorable risk Hodgkin's disease who achieve a partial response after 2 cycles of VAMP
chemotherapy.

3. To evaluate the efficacy of 2 alternating cycles of VAMP/COP chemotherapy (total 4
cycles of chemotherapy) plus low-dose, involved-field RT in children with intermediate
risk Hodgkin's disease.

4. To evaluate the efficacy of 12 weeks of Stanford V chemotherapy plus low-dose,
involved-field RT in children with unfavorable risk Hodgkin's disease.

Secondary Objectives:

1. To evaluate patient quality of life during and after treatment from the patient and
parent perspective.

2. To compare patient and parental ratings of treatment-related symptoms and patient
physical, psychological, social and cognitive functioning before the first treatment (T1
- baseline); after Cycle 2 or after 8 weeks of Stanford V (T2 - Evaluate Response);
after cycle 4 or after 12 weeks of Stanford V and before or on the first day of
radiation (as applicable) (T3); at the conclusion of radiation or within a few days
following the end of radiation (as applicable) (T4); and at 3 to 6 months after
completion of therapy follow-up evaluation (T5).

Inclusion Criteria:

- Eligible patients must have histologically confirmed previously untreated Hodgkin's
disease (Patients receiving limited emergent RT or steroid therapy because of
cardiopulmonary decompensation or spinal cord compression will be eligible for
protocol enrollment).

- Patients must be 21 years of age or younger

- Ann Arbor stages IIB-IV

- No prior treatment.

- No pregnant or lactating women.

- Signed informed consent

- If re-evaluation of a patient's disease shows favorable risk features or intermediate
risk features, the patient will be removed from the HOD99 study and consented to the
respective HOD08 or HOD05 study.

Inclusion: treatment of favorable risk features:

- Ann Arbor IA or IIA with:

1. Non-bulky mediastinal disease (<33% mediastinal to thoracic ratio on chest x ray)

2. Ann Arbor stage IA or IIA with any of the following features: (1) "E" lesions
(s), (2) 3 or more nodal sites involved, (3) Bulky mediastinal adenopathy
(mediastinal mass to thoracic cavity ratio 33% or greater by chest radiograph)

Inclusion: unfavorable risk features:

- Stage must be classified as one of the following:

1. Ann Arbor stage IIB, IIIB, or any IV